Silo Pharma Retail Buzz Surges On FDA Toxicology Study Plans For PTSD Treatment
The company announced FDA-requested toxicology studies for its PTSD treatment SPC-15, fueling optimism for a 2025 IND submission and Phase 1 trial.
Stocktwits·7mo ago
After a Patent Win, Analysts Think This Penny Stock Can Gain 465% in 2025
Amid the dynamic biopharma landscape, this penny stock is turning heads with a game-changing patent win, and analysts are buzzing with bullish projections for its potential.
barchart.com·11mo ago
Why This Small-Cap Biopharma Is Getting The Most Retail Attention On Stocktwits Today
Silo Pharma’s shares more than doubled yesterday as retail investors flock to the stock, driven by a promising new Alzheimer’s drug agreement.